Peng He
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Investigating the effects and underlying mechanisms of glycosylation sites on the immunogenicity of COVID-19 vaccines.
Journal: Signal transduction and targeted therapy
Published: May 06, 2025
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.
Journal: Expert review of vaccines
Published: January 21, 2025
Liposome-loaded dissolvable microneedle patches for more efficient intradermal antigen delivery of Hepatitis B vaccine.
Journal: International journal of pharmaceutics
Published: September 02, 2024
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Journal: Human vaccines & immunotherapeutics
Published: October 26, 2023
Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms.
Journal: Pharmaceutics
Published: May 26, 2023
Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.
Journal: The Journal of infection
Published: October 26, 2022
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Journal: The Lancet. Child & adolescent health
Published: October 19, 2022
A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults.
Journal: Clinical and translational medicine
Published: April 30, 2022
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2.
Journal: Cell discovery
Published: October 28, 2021
The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
Journal: Signal transduction and targeted therapy
Published: October 01, 2021
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Journal: Chinese medical journal
Published: July 26, 2021
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Journal: Cellular & molecular immunology
Published: February 07, 2021
Last Updated: 09/26/2026